A Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single dose of brincidofovir administered intravenously in healthy adult subjects

Trial Profile

A Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single dose of brincidofovir administered intravenously in healthy adult subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs Brincidofovir (Primary)
  • Indications Adenovirus infections; Cytomegalovirus infections; Smallpox; Viral infections
  • Focus Adverse reactions
  • Sponsors Chimerix
  • Most Recent Events

    • 08 Oct 2017 Results presented at the IDWeek 2017
    • 02 Mar 2017 Complete clinical and pharmacokinetic data from all four cohorts are expected to be reported during the first half of 2017, according to a Chimerix media release.
    • 06 Jan 2017 Preliminary results published in the Chimerix Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top